Navigation Links
Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
Date:2/4/2013

TEWKSBURY, N.J. and TARPON SPRINGS, Fla., Feb. 4, 2013 /PRNewswire/ -- Matinas BioPharma, Inc., a biopharmaceutical company focused on the commercialization and development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions, announced today that Roelof Rongen , Matinas BioPharma's Chief Executive Officer, is scheduled to present at the NYC Medical Technology Forum on Tuesday, February 5, 2013 at 6 PM EST.

Mr. Rongen's presentation will include the Company's business outlook for 2013, an overview of the development of its lead product candidate, MAT9001 and its key milestones expected over the next 12 months.  Matinas BioPharma is developing MAT9001 for therapeutic applications, with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL) as the lead indications.  Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and conduct a human study in 2013.  Following positive data from this study, Matinas expects to commence its Phase 3 registration program in the first half of 2014. 

About Matinas BioPharma

Matinas BioPharma Inc. is a privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions.  The Company is developing the investigational drug MAT9001 for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL).  Matinas is building on its extensive, proprietary research and development capabilities of its founding management team.  The Matinas BioPharma team brings a cumulative multi-decade omega-3 pharmaceutical development experience to the Company with a proven track record, providing a unique perspective and capability for the development of the next generation of omega-3-fatty-acid-based pharmaceutical products. 

About The NYC Medical Technology Forum (NYC Medtech)

NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries have successful outcomes.  This unique program not only brings together companies and investors but all people that are involved from reporters, scientists, academia, trade organizations, international partners et. al. The NYC Medtech program introduces its participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum.  For more information about the NYC Medical Technology Forum visit www.nycmedtech.com.

CONTACT:   
Roelof Rongen
Matinas BioPharma, Inc.
+1-908-443-1870 
info@matinasbiopharma.com


'/>"/>
SOURCE Matinas BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
2. PDL BioPharma Announces Departure of Finance VP
3. PDL BioPharma Announces 2013 Regular Quarterly Dividends
4. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
5. FDAnews announces Biopharmaceutical Good Distribution Practices Summit
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. Robust Biopharmaceutical Pipeline Offers New Hope for Patients
8. Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
9. AAIPharma Appoints Senior Director of Biopharmaceutical Development
10. PDL BioPharma Announces Resignation of Chief Financial Officer
11. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
Breaking Medicine Technology:
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
Breaking Medicine News(10 mins):